MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast - Episode Library
  • Patient Community Day at ECTRIMS 2025
  • Multiple Sclerosis in 2025 – Key Developments to Date
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us

Q&A

Home
Q&A
Facebook Live

Facebook Live: Research Update – December 2019

MStranslate
December 5, 2019
Community, Q&A, Research
On December 4, 2019, Brett Drummond (Co-Founder of MStranslate and Chief Science Communicator) held a Facebook Live event to explain and discuss a number of recent important developments in multiple sclerosis...
Facebook Live

Facebook Live: Announcement & Research Update

MStranslate
August 16, 2019
Community, Q&A, Research
In our most recent Facebook Live Q&A, once again facilitated by our co-founder and chief science communicator, Brett Drummond, a special announcement was made. We were excited to share that, for the second...
Facebook Live

Taking The Opportunity To Talk

MStranslate
February 28, 2019
Community, Genetics, Q&A
Next week, we are holding another one of our Facebook Live Q&A sessions.  For this event, the theme will be genetics in multiple sclerosis.  It will provide us an opportunity to discuss a number of key...
Terry Wahls

Interview Series on Diet & MS with Dr Terry Wahls

MStranslate
April 26, 2018
Diet, Lifestyle, Q&A, Research, Videos
In April, MStranslate co-founder, Brett Drummond, had the privilege of interviewing Dr Terry Wahls, visiting Australia from the University of Iowa.  Their conversation was published as a two part feature,...
pilates

Facebook Live Event: Pilates & Multiple Sclerosis

MStranslate
November 20, 2017
Community, Events, Q&A, Uncategorized
Broadcast date: Thursday 9th November, 2017 Our most recent Facebook Live event took place on location at Pilates on Bourke in Melbourne, Australia.  On this occasion, Brett was joined by MStranslate...
MS progression

Rates of MS Progression: Dr Tomas Kalincik (MSBase)

MStranslate
October 11, 2016
Q&A, Research
Upon his return from ECTRIMS 2016, Dr Tomas Kalincik from the Melbourne Brain Centre at Royal Melbourne Hospital spoke to MStranslate about recently published research by MSBase investigators.  Their...
Q&A

Upcoming MS Researcher Q&A Announcement

MStranslate
July 12, 2016
Community, Q&A, Videos
We love providing the opportunity for members of our community to interact directly with MS researchers from around the world. Whilst our Google Hangouts have been really well received in the past, we know...
  1. 1
  2. 2

Recent Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Recent Comments

  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date
  • Treatment With Gut Bacteria Shows Benefits In New Study on Gut Bacteria in People Living with RRMS
  • Community Q&A: COVID-19 Vaccines & Multiple Sclerosis on Community Q&A: The Blood-Brain Barrier
  • Community Q&A: Why Don't We Have A Multiple Sclerosis Cure? on Community Q&A: COVID-19 Vaccines & MS
  • Tim Little on FAKE NEWS ALERT: COVID Vaccines & MS

Calendar

March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
« Jan    

Archives

Categories

Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.